Share this article on:

iPad Extras: Audio Reports from the ASH Annual Meeting

doi: 10.1097/01.COT.0000461882.43062.18
News
Back to Top | Article Outline

Hear these podcast interviews on the iPad edition of this issue by OT reporters Sarah Maxwell and Peter Goodwin:

Figure

Figure

Figure

Figure

CAR Targeting CD19 T-Cells: Durable Remissions in Children with Relapsed, Refractory ALL

Stephan A. Grupp, MD, PhD, Professor of Pediatrics and Director of Translational Research at the Center for Childhood Cancer Research at Children's Hospital of Philadelphia, discussed his team's study showing that for children with relapsed and refractory acute lymphoblastic leukemia, engineered T-cells that target CD19 appeared to induce durable responses without the need for subsequent therapy such as stem cell transplantation (Abstract 380, OT 1/25/15 issue).

Figure

Figure

Vosaroxin Added to Cytarabine Extended Survival in First-Relapsed or Refractory AML

Farhad Ravandi, MD, Professor of Medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, discussed the results of the Phase III VALOR study showing that the quinolone derivative vosaroxin added to cytarabine should be considered a new standard for salvage therapy in patients with relapsed or refractory acute myeloid leukemia. The multinational study is one of the largest ever conducted in this group of patients, including some 700 patients randomized to receive either the new agent or a placebo combined with cytarabine therapy (Abstract LBA-6; OT 1/25/15 issue). Also commenting is David P. Steensma, MD, Associate Professor of Medicine, Hematologic Oncology, at Harvard Medical School, who moderated a news conference at the meeting that featured the study.

Figure

Figure

Myeloma: Triple Therapy Extends Survival in Relapsed Disease

A. Keith Stewart, MD, Dean for Research and Professor of Cancer Research at the Mayo Clinic in Arizona, discusses the much-talked-about ASPIRE study showing that the three-drug combination of lenalidomide, dexamethasone, and carfilzomib, increases progression-free survival to an “unprecedented” level and improves complete remission rates in patients with relapsed multiple myeloma (Abstract 79, OT 1/10/15 issue). Also commenting is Brad H. Kahl, MD, Clinical Research Director for Hematologic Malignancies at the University of Wisconsin Carbone Cancer Center.

Figure

Figure

If you are not yet receiving our iPad issues, download the free Oncology Times app from the App Store today! Visit http://bit.ly/OT-iPadApp , search in the App Store, or follow the link on oncology-times.com.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!